Research programme: alpha-emitting monoclonal antibody radiopharmaceuticals - Actinium Pharmaceuticals

Drug Profile

Research programme: alpha-emitting monoclonal antibody radiopharmaceuticals - Actinium Pharmaceuticals

Alternative Names: AA-A225; Ac-225 labeled anti-A33 monoclonal antibody; Ac-225-labeled anti-CD45 monoclonal antibody; Ac-255 labeled AA; Actimab-B; Actimab-Br; Actimab-C; Actimab-P; Actinium-225 labeled daratumumab; anti-A33 monoclonal antibody Ac-225; anti-CD45 monoclonal antibody BC8-Ac-225

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Memorial Sloan-Kettering Cancer Center
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain cancer; Colorectal cancer; Haematological malignancies; Multiple myeloma; Prostate cancer

Most Recent Events

  • 11 Apr 2018 Pharmacodynamics data from a preclinical trial in Multiple myeloma released by Actinium Pharmaceuticals
  • 12 Mar 2018 Preclinical development for Prostate cancer and Colorectal cancer is ongoing (Actinium Pharmaceuticals pipeline, March 2018)
  • 12 Mar 2018 Preclinical trials in Brain cancer in USA (Parenteral) (Actinium Pharmaceuticals pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top